16:43 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

Jardiance meets in pair of Phase III trials for Type I diabetes

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) said once-daily oral Jardiance empagliflozin as an adjunct to insulin met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo...
21:18 , Jun 29, 2018 |  BC Week In Review  |  Company News

Boehringer Ingelheim invests €230M in new biologics center

Boehringer Ingelheim GmbH (Ingelheim, Germany) will invest €230 million ($268 million) in a new biologicals development center at its R&D site in Biberach, Germany. The center will house 500 employees following a staggered launch beginning in...
17:50 , Jun 29, 2018 |  BioCentury  |  Regulation

Biosimilars do-over

As part of an initiative to stimulate biosimilar competition, FDA is planning a do-over of draft guidance on statistical methods for demonstrating biosimilarity to a reference product. The agency announced on June 21 it was...
19:19 , Jun 22, 2018 |  BC Week In Review  |  Company News

AHA, ADA partner with industry to launch diabetes, cardiovascular disease initiative

The American Heart Association and American Diabetes Association partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany), Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) to launch a 3.5 year initiative to help...
18:27 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Novo's oral GLP-1 analog meets primary in Phase IIIa trials compared with approved therapies

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing HbA1c and led to greater body weight reductions than both drugs in a...
20:52 , Jun 21, 2018 |  BC Extra  |  Clinical News

Novo expands market cap on oral semaglutide data

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) added DKK20.4 billion ($3.2 billion) in market cap in Copenhagen on Thursday after reporting that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing...
22:54 , Jun 20, 2018 |  BC Extra  |  Preclinical News

Broad ErbB inhibition arrests KRAS mutant cancer

Multi-ErbB inhibitors may provide a treatment option for K-Ras (KRAS)-driven lung cancer where ErbB family member EGFR1-specific therapies have failed, according to two studies published in Science Translational Medicine on Wednesday. The findings suggest a way...
15:26 , May 25, 2018 |  BC Week In Review  |  Financial News

Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed on May 21 a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and...
23:22 , May 21, 2018 |  BC Extra  |  Financial News

Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and FMB Research’s Franklin...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors...